Posted by Michael Wonder on 25 Feb 2021
Dascena announces FDA breakthrough device designation granted to machine learning diagnostic method
24 February 2021 - Algorithm for earlier detection of gastro-intestinal bleeding.
Dascena today announced that the U.S. FDA has granted breakthrough device designation to the company’s GI Bleed Risk Alert System (Gibras).
Gibras is a cloud-based software application that uses a machine learning algorithm to analyse patient electronic health record data to aid in the early prediction of gastro-intestinal bleeding in adult patients in a hospital setting.
